{"id":220,"date":"2020-05-20T12:02:23","date_gmt":"2020-05-20T12:02:23","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=220"},"modified":"2020-05-20T12:02:23","modified_gmt":"2020-05-20T12:02:23","slug":"19-may-2020-tocilizumab-may-offer-short-term-survival-benefit-in-severe-ill-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/19-may-2020-tocilizumab-may-offer-short-term-survival-benefit-in-severe-ill-patients\/","title":{"rendered":"(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1101\/2020.05.14.20099234<\/p>\n<p class=\"\">In an observational study, among 86 patients, 21 received Tocilizumab during the hospital stay. Both the Cox model and treatment effects models showed short-term survival benefit. There was an associated 75% reduction in the risk of inpatient death when treated (HR 0.25; 95% CI 0.07-0.90) in the Cox model. This association was confirmed in the treatment effects model where we found a 52.7% reduced risk of dying while hospitalized compared to those not treated (RR 0.472; 95% CI 0.449-0.497). In both models, we show short-term survival benefit in patients with severe COVID-19 illness.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study https:\/\/doi.org\/10.1101\/2020.05.14.20099234 In an observational study, among 86 patients, 21 received Tocilizumab during the hospital stay. Both the Cox model&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/19-may-2020-tocilizumab-may-offer-short-term-survival-benefit-in-severe-ill-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/220"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=220"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/220\/revisions"}],"predecessor-version":[{"id":221,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/220\/revisions\/221"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}